FindTrial
Sign In

Study on the safety of high-flow nasal oxygen therapy with different flow rates in obese patients undergoing sedative gastroscopy

Study on the safety of high-flow nasal oxygen therapy with different flow rates in obese patients undergoing sedative gastroscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095456
Enrollment
Unknown
Registered
2025-01-07
Start date
2024-10-23
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group HFNC30L/min:high-flow nasal cannulala 30L/min
Group HFNC70L/min:high-flow nasal cannulala 70L/min
Group HFNC50L/min:high-flow nasal cannulala 50L/min

Sponsors

NanJing First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing sedative gastroscopy; 2. Age 18-65 years old. 3. ASA classification I-III; 4. BMI 30kg/m^2-40 kg/m^2; 5. Interincisal distance >6.5cm, no micrognathia, limited mouth opening and limited cervical spine movement; 6. Compliance with ethics, patient willing to participate in the trial, signed informed consent form;

Exclusion criteria

Exclusion criteria: 1. Contraindications for endoscopic procedures or patients refusing sedation/anesthesia. 2. Patients with allergies to propofol, eggs, soybeans, or milk. 3. Patients with gastrointestinal obstruction and gastric emptying disorders. 4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections. 5. Patients with acute exacerbations of respiratory diseases such as asthma, bronchitis, and COPD. 6. Patients with acute arrhythmias and severe heart disease (congenital, valvular disease). 7. Patients requiring replacement therapy for severe liver or kidney dysfunction. 8. Patients with severe mental illnesses requiring medication to control symptoms. 9. Patients with moderate to severe anemia, coagulation disorders, and hematological diseases. 10. Patients with severe nasal congestion caused by nasal cavity lesions. 11. Pregnant and lactating patients.

Design outcomes

Primary

MeasureTime frame
The incidence of hypoxia in obese patients undergoing sedative gastroscopy using HFNC 30L/min, 50L/m;—

Secondary

MeasureTime frame
Airway interventions (jaw lift , increasing oxygen flow, mask ventilation, intubation);Occurrence of adverse reactions other than hypoxia (body movements, vomiting, reflux, bronchospasm,;occurrence of respiratory depression and severe hypoxia;—

Countries

China

Contacts

Public ContactWang Xiaoliang

NanJing First Hospital

wxl145381@njmu.edu.cn+86 25 52271030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026